Reduction of inflammation in chronic pancreatitis using a soy bread intervention: A feasibility study.
Aged
Bread
Cytokines
/ blood
Dose-Response Relationship, Drug
Feasibility Studies
Female
Humans
Inflammation
/ diet therapy
Inflammation Mediators
/ blood
Isoflavones
/ urine
Male
Middle Aged
Pancreatitis, Chronic
/ diet therapy
Patient Compliance
Pilot Projects
Glycine max
Tumor Necrosis Factor-alpha
/ blood
Feasibility study
IL-6
Isoflavones
Soy bread
TNF-Alpha
Journal
Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
ISSN: 1424-3911
Titre abrégé: Pancreatology
Pays: Switzerland
ID NLM: 100966936
Informations de publication
Date de publication:
Jul 2020
Jul 2020
Historique:
received:
30
01
2020
revised:
20
04
2020
accepted:
27
04
2020
pubmed:
1
7
2020
medline:
10
7
2021
entrez:
30
6
2020
Statut:
ppublish
Résumé
Chronic pancreatitis is a chronic inflammatory disease, which progresses to fibrosis. Currently there are no interventions to delay or stop the progression to irreversible organ damage. In this study, we assessed the tolerability and feasibility of administering soy bread to reduce circulating inflammatory mediators. Subjects with chronic pancreatitis diagnosed using the American Pancreatic Association diagnostic guidelines were enrolled. During the dose escalation (DE) phase, subjects received one week of soy bread based using a 3 + 3 dose-escalation design, which was then followed by a maximally tolerated dose (MTD) phase with four weeks of intervention. Dose-limiting toxicities (DLTs) were monitored. Plasma cytokine levels were measured using a Meso Scale Discovery multiplex assay kit. Isoflavonoid excretion in 24-h urine collection was used to measure soy bread compliance. Nine subjects completed the DE phase, and one subject completed the MTD phase without any DLTs at a maximum dosage of three slices (99 mg of isoflavones) per day. Reported compliance to soy bread intervention was 98%, and this was confirmed with urinary isoflavones and their metabolites detected in all subjects. There was a significant decline in the TNF-α level during the DE phase (2.667 vs 2.382 pg/mL, p = 0.039); other levels were similar. In this feasibility study, there was excellent compliance with a short-term intervention using soy bread in chronic pancreatitis. Reduction was seen in at least one pro-inflammatory cytokine with short-term intervention. Larger cohorts and longer interventions with soy are warranted to assess the efficacy of reducing pro-inflammatory mediators of disease.
Identifiants
pubmed: 32595109
pii: S1424-3903(20)30148-4
doi: 10.1016/j.pan.2020.04.018
pmc: PMC7780088
mid: NIHMS1613050
pii:
doi:
Substances chimiques
Cytokines
0
Inflammation Mediators
0
Isoflavones
0
Tumor Necrosis Factor-alpha
0
Types de publication
Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
852-859Subventions
Organisme : NIDDK NIH HHS
ID : U01 DK108327
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002733
Pays : United States
Informations de copyright
Copyright © 2020 IAP and EPC. Published by Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest No conflicts of interest exist.
Références
Am J Clin Nutr. 1991 Dec;54(6):1093-100
pubmed: 1659780
Nutr Rev. 2003 Apr;61(4):117-31
pubmed: 12795445
Nephrol Dial Transplant. 2006 Aug;21(8):2239-46
pubmed: 16766544
Pancreas. 2014 Nov;43(8):1143-62
pubmed: 25333398
J Nutr Biochem. 2011 May;22(5):502-10
pubmed: 20801632
Food Funct. 2012 Oct;3(10):1051-8
pubmed: 22739802
J Acad Nutr Diet. 2017 Apr;117(4):536-544.e2
pubmed: 27956174
Food Sci Technol Int. 2011 Jun;17(3):187-204
pubmed: 21593288
Nutr Cancer. 1994;21(2):113-31
pubmed: 8058523
Gastroenterology. 2012 Sep;143(3):655-663.e1
pubmed: 22683257
Pancreatology. 2016 Sep-Oct;16(5):692-3
pubmed: 27542963
Clin Nutr. 2006 Apr;25(2):275-84
pubmed: 16678943
Mediators Inflamm. 2018 Feb 1;2018:7946431
pubmed: 29563853
Proc Natl Acad Sci U S A. 2017 May 9;114(19):5011-5016
pubmed: 28439020
Dig Dis Sci. 2019 Aug;64(8):2318-2326
pubmed: 30798461
Cancer Prev Res (Phila). 2015 Nov;8(11):1036-44
pubmed: 26276751
Cancer Prev Res (Phila). 2015 Nov;8(11):1045-54
pubmed: 26276749
Phytomedicine. 2011 Feb 15;18(4):245-50
pubmed: 20732799
J Inflamm (Lond). 2007 Sep 07;4:17
pubmed: 17825101
Eur J Pain. 2010 Sep;14(8):792-8
pubmed: 20060762
Dig Dis Sci. 2017 Jul;62(7):1713-1720
pubmed: 28315036
Pancreatology. 2016 Mar-Apr;16(2):218-24
pubmed: 26924663
Br J Nutr. 2016 Feb 14;115(3):480-9
pubmed: 26489826
Am J Gastroenterol. 2020 Jan;115(1):49-55
pubmed: 31764092
Hepatology. 2009 Jun;49(6):2044-54
pubmed: 19444871
J Clin Gastroenterol. 2012 Oct;46 Suppl:S46-51
pubmed: 22955357
J Nutr. 2005 Dec;135(12):2786-92
pubmed: 16317121
Curr Opin Clin Nutr Metab Care. 2004 Nov;7(6):649-58
pubmed: 15534433
Int J Food Sci Nutr. 2014 Feb;65(1):9-20
pubmed: 24020353
Asia Pac J Clin Nutr. 2014;23(2):205-9
pubmed: 24901088
Dig Dis Sci. 2017 Jul;62(7):1745-1750
pubmed: 28281169
Pflugers Arch. 2017 Sep;469(9):1039-1050
pubmed: 28382480
J Agric Food Chem. 2013 Mar 27;61(12):3111-20
pubmed: 23451757
Gastroenterology. 2016 Dec;151(6):1206-1217
pubmed: 27769811
Immunol Res. 2012 Dec;54(1-3):95-110
pubmed: 22484990
J Nutr Biochem. 2011 May;22(5):401-8
pubmed: 21167699
J Nutr. 2000 Sep;130(9):2243-50
pubmed: 10958819
Eur J Clin Nutr. 2013 Jul;67(7):754-8
pubmed: 23594839
Gastroenterology. 2009 Jan;136(1):149-159.e2
pubmed: 18952082
Crit Rev Food Sci Nutr. 2010 Feb;50(2):130-45
pubmed: 20112156
Pancreas. 2018 Nov/Dec;47(10):1229-1238
pubmed: 30325862
Eur J Nutr. 2016 Mar;55(2):833-843
pubmed: 26026481
Circulation. 2003 Oct 21;108(16):1930-2
pubmed: 14530191
Pancreas. 2017 Sep;46(8):986-993
pubmed: 28796136